Endoxan

Acute Myeloid Leukemia

Celyad Oncology SAPhase 1Active

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 59/ 100

Competitive context

684 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China	Phase 3	BBB
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
Posaconazole AstraZeneca	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB

View all 50 →

Same molecule, other indications

Endoxan is also rated in:

plasma cell myelomaDormant

B

Indicative ·

61 / 100

peripheral T-cell lymphoma, not otherwise specifiedDormant

CCC

Indicative ·

53 / 100

triple-negative breast carcinomaDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.